During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.

Marseille, France, December 7, 2025, 5:30 pm ET/ 11:30 pm CET – ImCheck Therapeutics today announced updated results from its Phase I/II EVICTION study evaluating ICT01, a first-in-class ?9d2 T-cell ...

EVICTION is a first-in-human, dose-escalation (Part 1) and cohort-expansion (Part 2) clinical study of ICT01 in patients with various advanced relapsed or refractory solid or hematologic cancers that ...

CLN-049 has received FDA fast track designation for relapsed or refractory AML, highlighting its potential as a novel immunotherapy option. Initial phase 1 study results demonstrate meaningful ...

MIP CANCUN has lined up a panel discussion on micro-dramas with Inter Medya’s Can Okan, The Mediapro Studio’s JC Acosta and FlareFlow’s Shawn Wu, presented in association with TV Latina. Micro-dramas ...

Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...

Proteasome inhibitors have proven highly effective in multiple myeloma but not in acute myeloid leukemia. Proteasome inhibitors have proven highly effective in multiple myeloma but not in acute ...

Despite major advances in immunotherapy—including the 2025 Nobel Prize in Physiology or Medicine recognizing advances in peripheral immune tolerance—progress against leukemia has remained limited.

SEATTLE — A special edition of Conversations with KD Hall will be taped with a live audience on Sept. 17 as a part of a major sickle cell awareness effort and blood drive. From 10 a.m. to noon, ...

House Republicans voted on Wednesday to authorize a select subcommittee to investigate the Jan. 6, 2021, Capitol attack and potentially the previous Democratic-run Jan. 6 committee, a move that came ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. The heterogeneity of leukemic cells is the ...